Chemomab Therapeutics Advances Phase 3 Plans for Nebokitug
Chemomab Therapeutics Ltd. is advancing its Phase 3 plans for nebokitug, a monoclonal antibody targeting CCL24, aimed at treating primary sclerosing cholangitis (PSC). The company reported a cash position of $9.5 million, sufficient to fund operations through mid-2026. R&D expenses decreased to $1.3 million, while general and administrative expenses rose to $1.0 million. The net loss for the quarter was $2.1 million. Chemomab is also enhancing its intellectual property with new patents and plans a one-for-four reverse split to strengthen its market position.
Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, focuses on developing innovative treatments for fibro-inflammatory diseases with high unmet needs. The company is advancing its lead product, nebokitug, a monoclonal antibody targeting CCL24, which has shown promise in treating primary sclerosing cholangitis (PSC) and other severe conditions.
In its second-quarter 2025 financial report, Chemomab highlighted ongoing preparations for a Phase 3 trial of nebokitug in PSC, alongside efforts to secure strategic partnerships to optimize development and commercialization. The company has aligned with the FDA on regulatory requirements and is engaging with the European Medicines Agency for a global trial.
Key financial metrics for the quarter include a cash position of $9.5 million, expected to fund operations through mid-2026. Research and development expenses decreased significantly to $1.3 million, reflecting the completion of Phase 2 activities, while general and administrative expenses rose slightly to $1.0 million. The net loss for the quarter was $2.1 million, a reduction from the previous year.
Strategic developments include the issuance of new patents in China and Russia, enhancing nebokitug’s intellectual property portfolio, and a planned adjustment to the ADS ratio, effectively a one-for-four reverse split. These moves aim to strengthen Chemomab’s market position and support its ambitious clinical goals.
Looking ahead, Chemomab remains focused on advancing nebokitug through its Phase 3 trial and exploring value-creating initiatives to enhance the program’s success potential. The management is optimistic about securing partnerships that will accelerate development and maximize the drug’s commercial potential.
